Drugs / (R)-propafenone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02710669 | Oct 2016 → Mar 2020 | atrial fibrillation | Vanderbilt University | Terminated | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (R)-propafenone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02710669 ↗ |
| Action | Inhibit | “(R)-propafenone is an ryanodine receptor inhibitor” PMID 36166682 ↗ Sep 2022 |
| Route | Intravenous | “Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes” NCT02710669 ↗ |
| Target | RYR2 | “A Mechanistic Clinical Trial Using (R)- Versus (S)-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction.” PMID 36166682 ↗ Sep 2022 |